Clinical Trial Update: Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of imatinib mesylate, vatalanib, and hydroxyurea in patients with recurrent or relapsed malignant glioma has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Gleevec (Imatinib)
• HYDROXYUREA (Hydroxyurea)
• Vatalanib (vatalanib)

Snippet

Sponsor: Duke University | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED